News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.



Berlin, Germany, June 28, 2011 – Epigenomics AG‘s (ISIN: DE000A0BVT96) General Assembly today approved all decision proposals by the management with vast majority.

The proposal to reduce the share capital and to consolidate of the shares at a ratio of 5:1 was approved with more than 99.8 % of the present and represented voting rights. Following this approval, the capital shall be reduced from now EUR 44,092,085.00 to EUR 8,818,417.00. After the consolidation of the shares, the share capital shall be distributed into 8,818,417 shares. The reduction of share capital becomes effective only after its registration in the commercial register. The consolidation of the shares shall follow thereafter in the subsequent trading days.

An overview of all voting results of the General Assembly is available at Epigenomics AG’s internet page.

-End of Ad hoc –

Further Information

For the voting results and further information on Epigenomics AG’s Annual General Shareholder’s Meeting please visit

Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Phone: +49 (0) 30 24345 0

Epigenomics’ legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.